Comparative Pharmacology
Head-to-head clinical analysis: TETREX versus VIBRA TABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETREX versus VIBRA TABS.
TETREX vs VIBRA-TABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
100 mg orally twice daily on day 1, then 100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours.
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic